KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBITDA Margin: 2010-2015

Historic EBITDA Margin for Biocryst Pharmaceuticals (BCRX) over the last 4 years, with Sep 2015 value amounting to -132.25%.

  • Biocryst Pharmaceuticals' EBITDA Margin rose 13743.00% to -132.25% in Q3 2015 from the same period last year, while for Sep 2015 it was -81.18%, marking a year-over-year increase of 12677.00%. This contributed to the annual value of -333.06% for FY2014, which is 15921.00% down from last year.
  • Latest data reveals that Biocryst Pharmaceuticals reported EBITDA Margin of -132.25% as of Q3 2015, which was down 700.11% from 22.04% recorded in Q2 2015.
  • In the past 5 years, Biocryst Pharmaceuticals' EBITDA Margin ranged from a high of 1,059.05% in Q2 2012 and a low of -1,483.68% during Q2 2013.
  • For the 3-year period, Biocryst Pharmaceuticals' EBITDA Margin averaged around -373.30%, with its median value being -220.10% (2015).
  • As far as peak fluctuations go, Biocryst Pharmaceuticals' EBITDA Margin surged by 129,916bps in 2012, and later crashed by 254,273bps in 2013.
  • Quarterly analysis of 5 years shows Biocryst Pharmaceuticals' EBITDA Margin stood at -211.37% in 2011, then spiked by 129,916bps to 1,059.05% in 2012, then crashed by 254,273bps to -51.36% in 2013, then plummeted by 16,539bps to -216.75% in 2014, then skyrocketed by 13,743bps to -132.25% in 2015.
  • Its EBITDA Margin was -132.25% in Q3 2015, compared to 22.04% in Q2 2015 and -220.10% in Q1 2015.